Head-to-head · Cost-Efficiency Index
Maves vs EdgeRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Maves
Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Visit MavesEdgeRx
Men who also want adjacent peptide, longevity, and hormone protocols (MICC, sermorelin, NAD+, PT-141) bundled with GLP-1 on one account.
Visit EdgeRxThe verdict
Maves takes it, leading the Cost-Efficiency Index 76 to 74. Maves (operated by parent company Homera Health) is a men's-health/performance-framed telehealth platform offering compounded semaglutide and tirzepatide plus sermorelin. EdgeRx still earns a C — Men who also want adjacent peptide, longevity, and hormone protocols (MICC, sermorelin, NAD+, PT-141) bundled with GLP-1 on one account.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Maves.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Maves | EdgeRx |
|---|---|---|
| Cost-Efficiency Index | 76/100 | 74/100 |
| Semaglutide / mo | $89/mo (starting dose, compounded) | $229/mo (once-weekly injectable) |
| Tirzepatide / mo | Not disclosed | $299/mo (once-weekly injectable) |
| Semaglutide / yr (modeled) | $1,068 | $2,748 |
| Tirzepatide / yr (modeled) | — | $3,588 |
| Coverage | All 50 states | 46 states — excludes Arkansas, Indiana, Minnesota, South Carolina |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #49 | #55 |
Maves
76/100Where the value is
- LegitScript badge displayed on the site
- Publishes the FDA compounded-medication disclaimer
- Low advertised semaglutide entry price ($89-99/mo range)
The tradeoffs
- The homepage shows two different numbers for the same starting semaglutide tier ($89/month vs $99 first month) with no reconciliation — the real ongoing price cannot be confirmed from the public site
- Tirzepatide is listed as an offering but no price is published anywhere reachable on the site, confirmed by direct search
EdgeRx
74/100Where the value is
- Named Chief Medical Advisor (Dr. John Starke, MD, ABEM board-certified) sets clinical/dosing standards
- Named compounding pharmacy — Strive Pharmacy, a 503A facility operating since 2018
- LegitScript certified, with a specific, named state-exclusion list rather than a vague coverage claim
The tradeoffs
- Men's-only positioning — explicitly not a fit for women readers
- Dr. Starke sets standards but does not personally prescribe; the actual prescribing pool is an unnamed pool of licensed physicians
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.